Riu Yamashita

10PUBLICATIONS
129CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsComputational ecology and phylogenetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 17, 2026
Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer.

|Jan 27, 2026
Non-Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors.

Hiroki Ishihara, Yu-Yu Liu, Riu Yamashita

|May 09, 2025
Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study.

Kentaro Sawada, Riu Yamashita, Shunsuke A Sakai

|Feb 18, 2025
SpatialKNifeY (SKNY): Extending from spatial domain to surrounding area to identify microenvironment features with single-cell spatial omics data.

Shunsuke A Sakai, Ryosuke Nomura, Satoi Nagasawa

|Jan 17, 2025
Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial.

Mitsuho Imai, Yoshiaki Nakamura, Sangwon Shin

|Dec 12, 2024
Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration.

Shunsuke A Sakai, Koichi Saeki, SungGi Chi

Pageof 2

Frequent Collaborators

6 joint publications

Yoshiaki Nakamura

5 joint publications

Takao Fujisawa

5 joint publications

Takayuki Yoshino

5 joint publications

Hideaki Bando